← boardnext 2026-11
CGON
CG Oncology, Inc.distress 1/10 · well-funded / low risk$69.58+0%today-8% from 52w high
Lead: Non Muscle Invasive Bladder Cancer
Revenue
pre-revenue
Liquidity
$1076M
Runway
6.7 yrs
Shares 1y
+16%
Price & events
+24.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
+0.1%
1W
+5.9%
1M
-0.4%
3M
+29.3%
6M
+164.4%
1Y
+102.9%
2Y
—
5Y
+87.2%
All
Overview
- Market Cap
- $6.14B
- Enterprise Value
- $6.11B
- Volume
- 93.58K
- 52 Week Range
- $23.95 – $75.24
- Total Shares
- 88.20M
- Float Shares
- 65.82M
- Short %
- 13.93%
- % Held by Insiders
- 0.23%
- % Held by Institutions
- 109.81%
- RVOL
- 0.08x
- Beta
- 0.22
Pipeline stages · 1 programs
Cretostimogene Grenadenorepvec
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11 Estimated 50% readout ~2027-01-15 | Phase 3 | Cretostimogene Grenadenorepvecbreakthroughfast track | Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma | — | active not recruiting |
| 2027-03-31 Estimated 50% readout ~2027-05-15 | Phase 2 | Cretostimogene Grenadenorepvecbreakthroughfast track | High-Risk Non-Muscle-Invasive Bladder Cancer | — | recruiting |
| 2030-06-16 Estimated 50% readout ~2030-08-30 | Phase 3 | Cretostimogene Grenadenorepvecbreakthroughfast track | Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | — | active not recruiting |
Catalyst news & presentations · 6
- 2026-08-07Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026readoutPhase 3cretostimogene grenadenorepvec · Expedited topline data readout timeline.SEC 8-K
- September 5, 2025readoutPhase 3cretostimogene · Updated BOND-003 Cohort C data showing 12 additional patients in complete response at 24 months.SEC 8-K
- AUA Annual Meetingconferencedata presentationsecondaryPhase 3cretostimogene grenadenorepvec · Updated Cohort C and P efficacy and safety data presented at medical conference.SEC 8-K
- March 24, 2025readoutPhase 3cretostimogene · Updated topline data from BOND-003 Phase 3 trial presented at EAU CongressSEC 8-K
- at SUO 25th Annual Meetingconferencedata presentationsecondaryPhase 3cretostimogene · Late-breaking abstract presentation at SUO 2024SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $90 (+30% upside) · 14 analysts
- 2026-05-19Wolfe ResearchPeer Perform
- 2026-05-18HC Wainwright & Co.Buy
- 2026-05-14Truist SecuritiesBuy
- 2026-05-11Truist SecuritiesBuy
- 2026-05-11JP MorganOverweight
- 2026-05-11RBC CapitalOutperform
Competitors — Non Muscle Invasive Bladder Cancer
- RLMDRELMADA THERAPEUTICS, INC.$511M · D6
Recent news
- 2026-07-20CG Oncology: Priced To Perfection On Future Pipeline Success - Seeking Alpha
- 2026-07-17CG Oncology (CGON) director sells 1,000 shares at $71.17 - Stock Titan
- 2026-07-17CG Oncology director Leonard Post disposes of 1,000 shares for $71,170 - Bitget
- 2026-07-17CG Oncology director Leonard Post disposes of 1,000 shares for $71,170 - Bitget
- 2026-07-15Form 144 CG ONCOLOGY For: 15 July By Investing.com - Investing.com Nigeria
- 2026-07-15CG Oncology, Inc. SEC Filing (Jul 15, 2026) - Stock Titan
- 2026-07-15CG Oncology: Advancing Toward a Potential Breakthrough in Bladder Cancer Treatment - Kalkine
- 2026-07-14CG Oncology (CGON) Declines Moderately as Biotech Sector Faces Headwinds - Momentum ETF - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.